Expired activity

Please go to the PowerPak homepage and select a course.

Showing Patients with Migraine the Possibilities with CGRP mAbs

ACTIVITY OVERVIEW

This activity focuses on the latest data with calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) as well as personalized migraine treatment. Leading migraine experts, Jessica Ailani, MD, FAHS, FAAN and Richard Wenzel, PharmD discuss factors that influence treatment, strategies to improve therapeutic adherence, and comprehensive care strategies. 

Faculty

Jessica Ailani, MD, FAHS, FAAN
Director, MedStar Georgetown Headache Center
Washington, DC

Richard Wenzel, PharmD, CPPS
Consultant Pharmacist
Chicago Headache Center & Research Institute
Chicago, IL

TARGET AUDIENCE

This activity is intended for neurologists, headache specialists, and pharmacists who manage patients with migraine.

GOAL (ACTIVITY PURPOSE)

Migraine is ranked as the third most prevalent disorder and seventh-highest specific cause of disability worldwide, accounting for 30% of the global burden of disease and 50% of the world’s neurological disease-related disability. Migraine is such a common disorder that it is more prevalent than diabetes, epilepsy, and asthma combined. Current employment-related costs due to migraine-related lost productivity are estimated at more than $14 billion annually. Problematically, a 2016 study found that less than 5% of patients with chronic migraine received appropriate care, likely due to poor treatment adherence over the long term. 

Secondary to the significance of migraine coupled with the ongoing care gaps, healthcare providers need to be better prepared to develop effective treatment plans for patients with episodic and chronic migraine. Healthcare providers also need to improve their shared decision-making with their patients with migraine to ensure that patients’ goals and desires are incorporated into therapy selection. Upon completing this activity, healthcare providers will be better able to create appropriate, patient-centered episodic and chronic migraine treatment regimens.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, pharmacists will be able to:

• Interpret and discuss the efficacy, safety and tolerability of CGRP mAbs for the treatment of acute and chronic migraine
• Apply effective strategies for improving patient adherence to therapies
• Employ clinical shared decision-making strategies to address patient fears and promote optimal self-management

HOW TO EARN CREDIT

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A participation statement will be immediately available. There is no fee to participate in the activity or for the generation of the participation statement.

For questions, contact Karen Catino at kcatino@achlcme.org

FINANCIAL DISCLOSURE

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

The following financial relationships have been provided:

Jessica Ailani, MD, FAHS, FAAN
Sources of Funding for Research: Abbvie, Biohaven, Eli Lilly, Impel, Lundbeck, Satsuma, Zosano,
Consulting Agreements: Abbvie, Amgen, Aeon, BioDeliveryScience, Biohaven, Glaxo Smith Kline, Eli Lilly, Miravo, Nesos, Satsuma, Teva
Advisory Board: BioDeliveryScience, Impel, Lundbeck, Teva

Richard Wenzel, PharmD, CPPS
Employee: Eli Lilly & Company (2018- January 2022)

STAFF AND REVIEWER DISCLOSURES

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

ACCREDITATION STATEMENTS

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0396-0000-22-058-H01-P
Credits: This activity has been approved for 1.0 contact hours.

Type of Activity: Application
Media: Internet

ACTIVITY OUTLINE

Topic #1: Factors that influence treatment selection and adherence
Topic #2: The promise of CGRP mAbs in migraine prevention
Topic #3: Comprehensive care strategies
Topic #4: Enhancing shared decision-making in migraine care

Supported by an educational grant from Lundbeck.

DISCLOSURE OF UNLABELED USE AND DISCLAIMER

All content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with ACPE Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Published

September 30, 2022

Expires

June 30, 2023

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5